HBP.TO - Helix BioPharma Corp.

Toronto - Toronto Delayed Price. Currency in CAD
1.4500
-0.0900 (-5.84%)
At close: 10:21AM EDT
Stock chart is not supported by your current browser
Previous Close1.5400
Open1.5400
Bid1.4200 x 0
Ask1.4800 x 0
Day's Range1.4500 - 1.5400
52 Week Range0.2400 - 2.0100
Volume4,000
Avg. Volume6,834
Market Cap192.753M
Beta (5Y Monthly)0.17
PE Ratio (TTM)N/A
EPS (TTM)-0.0740
Earnings DateMar. 15, 2020
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est2.50
  • GlobeNewswire

    Helix BioPharma Corp. Provides Corporate Update

    As countries across the globe face an unprecedented public health crisis due to COVID-19, Helix has taken various measures to protect the health and well-being of our staff while maintaining business continuity. The Company’s U.S. Phase I L-DOS47 lung cancer study in combination with pemetrexed and carboplatin (LDOS001) has completed patient recruitment. As previously reported in the Company’s recently filed Q2 fiscal 2020 filings, the Company’s European Phase II L-DOS47 lung cancer study in Poland and Ukraine (LDOS003) no longer requires patient enrollment.

  • GlobeNewswire

    HELIX BIOPHARMA CORP. ANNOUNCES FISCAL SECOND QUARTER 2020 RESULTS

    RICHMOND HILL, Ontario, March 16, 2020 -- Helix BioPharma Corp. (TSX: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of.

  • GlobeNewswire

    Helix BioPharma Corp. Closes $6.0 Million Private Placement

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing of 5,042,016 units of the Company (“Units”) at a price of $1.0332 per Unit, and the concurrent disposition of 1,708,023 shares of the Company’s Polish subsidiary, Helix Immuno-Oncology S.A. (“HIO”), to a third-party purchaser, representing an 15.5% equity stake in HIO (together with the Units, the “Purchased Securities”), for aggregate gross proceeds of CAD $6,000,000, or $1.19 per Purchased Security. Each Unit is comprised of one common share and one common share purchase warrant.

  • GlobeNewswire

    Helix BioPharma Corp. to Present at the Noble Capital Markets’ Sixteenth Annual Investor Conference

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced that Dr. Heman Chao, Helix’s Chief Executive Officer, will be presenting at NobleCon - Noble Capital Markets’ Sixteenth Annual Investor Conference at the Hard Rock Hotel & Casino, Hollywood, Florida - on Monday, February 17th at 3:00PM Eastern Standard Time (https://www.nobleconference.com/sixteen#home). In addition to the company’s presentation on Monday, February 17th Dr. Chao has been invited to be a panelist on “Cancer Treatment: Tackling the Disease Through Innovative Strategies”.

  • GlobeNewswire

    Helix BioPharma Corp. Closes $3.0 Million Private Placement

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing of 2,940,000 units of the Company (“Units”) and the disposition of shares of the Company’s Polish subsidiary, Helix Immuno-Oncology S.A. (“HIO”), representing an 8.5% stake in HIO (together with the Units, the “Purchased Securities”) for aggregate gross proceeds of approximately CAD $3,000,000, or $1.02 per Purchased Security. Each Unit is comprised of one common share and one common share purchase warrant.

  • GlobeNewswire

    Helix BioPharma Corp. to Present at the Biotech Showcase Conference in San Francisco

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has been selected to present at the Biotech Showcase Conference on Tuesday, January 14, 2020 at 11:00am (PT) at Hilton San Francisco Union Square. Biotech Showcase Conference, produced by Demy-Colton and EBD Group, is an investor and networking conference devoted to providing private and public biotechnology and life sciences companies with an opportunity to present to, and meet with, investors and pharmaceutical executives in one place during the course of one of the industry's largest annual healthcare investor conferences, J.P. Morgan Annual Healthcare Conference.

  • GlobeNewswire

    Helix BioPharma Corp. Announces Fiscal First Quarter 2020 Results

    RICHMOND HILL, Ontario, Dec. 13, 2019 -- Helix BioPharma Corp. (TSX, FSE: “HBP”), a an immuno-oncology company developing drug candidates for the prevention and treatment of.

  • GlobeNewswire

    Helix BioPharma Corp. Commences L-DOS47 Phase lb/ll Pancreatic Cancer Clinical Study

    The study is entitled “A Phase Ib/II Study of the Microenvironment Modifier L-DOS47 plus Doxorubicin for the Treatment of Patients with Previously Treated Advanced Pancreatic Cancer”. Pancreatic cancer is the third leading cause of cancer death in the United States for which there are few treatment options.

  • GlobeNewswire

    Helix BioPharma Corp. Reports Voting Results

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the voting results of the Company’s annual and special meeting of shareholders held on December 6, 2019 (the “Meeting”). There were 20 shareholders represented in person or by proxy at the Meeting holding 83,464,785 common shares, representing approximately 66.80% of Helix’s total issued and outstanding shares. BDO Canada LLP, Chartered Professional Accountants, was appointed auditor of Helix until the next annual meeting of shareholders at remuneration to be fixed by the directors.

  • Will Helix BioPharma (TSE:HBP) Spend Its Cash Wisely?
    Simply Wall St.

    Will Helix BioPharma (TSE:HBP) Spend Its Cash Wisely?

    Just because a business does not make any money, does not mean that the stock will go down. For example, Helix...

  • ACCESSWIRE

    MicroCap Review Magazine Fall 2019 Issue Now Available

    The Digital Issue of the Fall 2019 MicroCap Review Magazine, The Official Magazine for the MicroCap Stock Market, can be read on www.StockNewsNow.com LOS ANGELES, CA / ACCESSWIRE / November 20, 2019 / ...

  • GlobeNewswire

    Helix BioPharma Corp. Announces Fiscal 2019 Year-End Results

    RICHMOND HILL, Ontario, Oct. 25, 2019 -- Helix BioPharma Corp. (TSX: “HBP”), an immuno-oncology company developing drug candidates for the prevention and treatment of cancer,.

  • GlobeNewswire

    Helix BioPharma Corp. Board Changes

    RICHMOND HILL, Ontario, Oct. 10, 2019 -- Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the.

  • GlobeNewswire

    Helix BioPharma Corp. and Moffit Cancer Centre to Present at World Molecular Imaging Congress

    The poster presentation will take place at the World Molecular Imaging Congress (“WMIC”), which is taking place at the Palais des congrès de Montréal in Montréal, Quebec, Canada (http://www.wmis.org/2019-wmic/) on September 4th through the 7th, 2019. The presentation describes the use of functional imaging techniques to measure the effect of L-DOS47 on changing tumor pH in a pancreatic mouse model.  The pH effect can be measured by CEST MRI using a CT contrast agent iopamidol and by 31P-MRS with 3-aminopropyl phosphate (“3-APP”) as reporting agent.  In both cases, L-DOS47 injection is shown to induce a localized pH increase at the target tumor.   L-DOS47 pH effect may also have a direct impact on therapy as combined treatment of L-DOS7 with an anti-PD-1 antibody is more efficacious than either agent alone in a preliminary round of animal study.

  • GlobeNewswire

    Helix BioPharma Corp. Closes $7.0 Million Private Placement

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing of 13,725,000 units of the Company and the disposition of a 25% stake of its wholly-owned Polish subsidiary for aggregate gross proceeds of CAD $7,000,005. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $0.72 and have an expiry of five years from the date of issuance.

  • GlobeNewswire

    Helix Biopharma Corp. Receives U.S. FDA Approval for Phase Ib/II Pancreatic Trial

    Helix BioPharma Corp. (HBP.TO), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced that it has received approval from the U.S. Food and Drug Administration (“FDA”), to initiate a Phase Ib/II study of L-DOS47 and doxorubicin in advanced metastatic pancreatic cancer. This is an open label, non-randomized study designed to evaluate the safety, tolerability and preliminary activity of L-DOS47 in combination with doxorubicin in patients with metastatic pancreatic cancer who have progressed on at least two prior treatment regimens.

  • GlobeNewswire

    Helix Biopharma Corp. to Present at RHK Capital Conference in New York

    Helix BioPharma Corp. (HBP.TO), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announces that it will be presenting at the RHK Capital 2019 Disruptive Growth & Healthcare Conference (www.disruptnyc.com). RHK Capital’s Disruptive Growth & Healthcare Conference showcases life science companies that focus on solutions for unmet medical needs and growth companies with disruptive technologies and business models.  The 2019 Disruptive Growth & Healthcare Conference will be held on Wednesday, September 4th and Thursday, September 5th in New York. “We are pleased to present Helix at this venue,” said Dr. Heman Chao, Helix’s Chief Executive Officer.  “As part of the Company’s objective to increase awareness of the Company’s novel DOS47 tumor microenvironment platform, the Company will be actively participating in select conferences and non-deal roadshows during the second half of calendar 2019”.

  • GlobeNewswire

    Helix BioPharma Corp. Submits L-DOS47 IND Application With U.S. FDA for Pancreatic Cancer

    Helix BioPharma Corp. (HBP.TO), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced the submission of an Investigational New Drug (“IND”) application with the U.S. Food and Drug Administration (“FDA”) for approval to initiate a Phase I/II clinical study protocol with L-DOS47, to be given in combination with doxorubicin, for the treatment of metastatic pancreatic cancer. Pancreatic cancer is the seventh leading cause of cancer related deaths in the world.  In the United States alone, it is estimated that over 56,000 adults will be diagnosed with the disease and over 45,000 patients will succumb to the disease, this year.  The 5-year survival rate for those who suffer from late stage metastatic pancreatic cancer is 3%.

  • GlobeNewswire

    Helix BioPharma Corp. Announces Fiscal Third Quarter 2019 Results

    RICHMOND HILL, Ontario, June 11, 2019 -- Helix BioPharma Corp. (TSX: HBP) (“Helix” or the “Company”), a clinical stage immuno-oncology company developing innovative drug.

  • GlobeNewswire

    Helix BioPharma Corp. Initiates OTCQB Application and Hires U.S. Investor Relations Firm

    Helix BioPharma Corp. (HBP.TO), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, announced that it has commenced the process to have the Company’s common shares quoted on the OTCQB® Market exchange in the United States. The Company’s U.S. legal counsel, Sheppard Mullin, Richter and Hampton LLC will be acting as Principal American Liaison (“PAL”) in assisting the Company through the listing application process. Expanding to the OTCQB® will provide existing shareholders with an additional trading platform to the Toronto Stock Exchange in addition to introducing the Company to a broader range of institutional and retail investors in the U.S. Listing on the OTCQB® represents a first step in fulfilling the Company’s ambitions to list on a U.S. stock exchange, such as NASDAQ.

  • GlobeNewswire

    Helix BioPharma Corp. Closes Private Placement

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a private placement financing for gross proceeds of CAD507,960. Each unit is comprised of one common share and one common share purchase warrant. Each common share purchase warrant will entitle the holder to purchase one common share at an exercise price of $0.72 and have an expiry of five years from the date of issuance.  Helix intends to use the net proceeds of the private placement for working capital and research and development activities.

  • GlobeNewswire

    L-DOS47 Phase II Randomized Study Advances to Second Cohort

    Helix BioPharma Corp. (HBP.TO), (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, has announced that the Trial Steering Committee ("TSC") reviewed safety data from the first dosing cohort of the Company’s LDOS003 study.  No serious adverse events or dose limiting toxicities were observed.  TSC recommended that Helix begin enrollment of patients into the second dosing cohort. LDOS003 is a Phase II, open-label, randomized study of immunoconjugate L-DOS47 in combination with vinorelbine and cisplatin as compared to vinorelbine and cisplatin alone in patients with lung adenocarcinoma.

  • GlobeNewswire

    Helix BioPharma Corp. Closes Second Tranche of Private Placement

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a second tranche of a private placement financing for gross proceeds of CAD510,000. The Company is working on completing another private placement financing tranche by May 17, 2019. Each unit is comprised of one common share and one common share purchase warrant.

  • GlobeNewswire

    Helix BioPharma Corp. Closes First Tranche of Private Placement

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has closed a first tranche of a private placement financing for gross proceeds of approximately CAD1,016,390. The Company expects to complete subsequent private placement financing tranches by May 17, 2019. Each unit is comprised of one common share and one common share purchase warrant.

  • GlobeNewswire

    Helix BioPharma Corp. Retains U.S. Legal and Capital Firms to Advise on U.S. Listing

    Helix BioPharma Corp. (TSX: “HBP”) (“Helix” or the “Company”), an immuno-oncology company developing innovative drug candidates for the prevention and treatment of cancer, today announced it has retained Sheppard Mullin, Richter and Hampton LLC (“Sheppard Mullin”) and RHK Capital (“RHK”). Sheppard Mullin will advise the Company on U.S. general corporate matters and securities law as the Company looks towards the U.S. capital markets.